Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: A Kansai clinical oncology group study (KCOG0330)

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1073-1080

  Tsubamoto, Hiroshi ^a   Kawaguchi, Ryuji ^b   Ito, Kimihiko ^c   Shiozaki, Takaya ^d   Takeuchi, Satoshi ^e   Itani, Yoshio ^f   Arakawa, Atsushi ^g   Tabata, Tsutomu ^d   Toyoda, Shinji ^f  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

^d MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e IWATE MEDICAL UNIVERSITY   (Japan)

^f NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^g NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Carboplatin; Chemotherapy; Irinotecan; Ovarian cancer

Indexed keywords

CARBOPLATIN; IRINOTECAN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; ILEUS; INTENTION TO TREAT ANALYSIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; PARAMETERS; PHASE 2 CLINICAL TRIAL; PLATINUM FREE INTERVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CAMPTOTHECIN; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84875907940     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X and Hamilton TC: Focus on epithelial ovarian cancer. Cancer Cell 5: 19-24, 2004.
2. Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A and Mangioni C: Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: An Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer 90: 2112-2117, 2004.
3. Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E and Lichtenegger W: Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: Results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26: 3176-3182, 2008.
4. Pujade-Lauraine E, Paraiso D, Joly F, Provencal J, Goupil A, Provencal J, Goupil A, Mayeur D, Plaza J, Barats JC and Netter- Pinon VG: Is there a role for platinum in the treatment of patients with "platinum-resistant" relapsed advanced ovarian cancer (AOC)? A GINECO study. Proc Am Soc Clin Oncol 22(suppl): abstr 1811, 2003.
5. Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Selvaggi L, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Marforio G, Ballardini M, Lombardi AV, Sorio R, Tumolo S, Costa B, Magni G, Perrone F and Favalli G: Extending the platinum-free interval with a nonplatinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology 71: 320-326, 2006.
6. Tanguay JS, Ansari J, Buckley L and Fernando I: Epithelial ovarian cancer: Role of pegylated liposomal doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment. Int J Gynecol Cancer 19: 361-366, 2009.
7. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A and Trope C: Paclitaxel plus platinum-based chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106, 2003.
8. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stahle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Luck HJ, Rochon J, Zimmermann AH and Eisenhauer E: Gemcitabine plus carboplatin compared with carboplatin in patients with platinumsensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24: 4699-4707, 2006.
9. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N and du Bois A: Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28: 3323-3329, 2010.
10. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S and Miura Y: Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 50: 604-610, 1992.
11. Minagawa Y, Kigawa J, Ishihara H, Itamochi H and Terakawa N: Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 85: 966-971, 1994.
12. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M and Saijo N: Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 56: 789-793, 1996.
13. Yonemori K, Katsumata N, Yamamoto N, Kasamatsu T, Yamada T, Tsunematsu R and Fujiwara Y: A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer 104: 1204-1212, 2005.
14. Thigpen T: A rational approach to the management of recurrent or persistent ovarian carcinoma. Clin Obstet Gynecol 55: 114-130, 2012.
15. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME and Lacave AJ: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322, 2001.
16. Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr., Marciniack M, Naumann RW and Secord AA: Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25: 2811-2818, 2007.
17. Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G and Kaye S: Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or - resistant ovarian cancer. Eur J Cancer 45: 2324-2332, 2009.
18. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag DT and Ray-Coquard L: AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 30 (suppl) abstr LBA5002, 2012.
19. Matsumoto K, Katsumata N, Yamanaka Y, Yonemori K, Kohno T, Shimizu C, Andoh M and Fujiwara Y: The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes -resistant epithelial ovarian cancer. Gynecol Oncol 100: 412-416, 2006.
20. Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, Slama B, Dauba J, Paraiso D and Pujade-Lauraine E: Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol 23: 346-352, 2012.
21. Sehouli J, Meier W, Wimberger P, Chekerov R, Belau A, Mahner S, Kurzeder C, Hilpert F, Klare P, Doerfel S, Hans-Georg Strauss H, Canzler U, Marth C, Reinthaller A, Petru E, Richter R, Rubio MJ, Bover I, Gonzalez-Martin A and Harter P: Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR). J Clin Oncol 30(suppl): abstr 5031, 2012.
22. Koensgen D, Stengel D, Belau A, Klare P, Oskay-Oezcelik G, Steck T, Camara O, Mustea A, Sommer H, Coumbos A, Bogenrieder T, Lichtenegger W and Sehouli J: Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO phase I/II study. Cancer Chemother Pharmacol 62: 393-400, 2008.
23. Rose PG, Monk BJ, Provencher D, Hartney J, Legenne P and Lane S: An open-label, single-arm Phase II study of intravenous weekly (days 1 and 8) topotecan in combination with carboplatin (day 1) every days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer. Gynecol Oncol 120: 38-42, 2011.
24. Murata Y, Hirose T, Yamaoka T, Shirai T, Okuda K, Sugiyama T, Kusumoto S, Nakashima M, Ohmori T and Adachi M: Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small cell lung cancer. Eur J Cancer 47: 1336-1342, 2011.
25. Horn L, Zhao Z, Sandler A, Johnson D, Shyr Y, Wolff S, Devore RF and Laskin J: A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. Clin Lung Cancer 12: 161-165, 2011.
26. Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE and Keilholz U: A German multicenter, randomized phase III trial comparing irinotecancarboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 22: 1798-1804, 2011.
27. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A and Saijo N: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: Roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17: 497-504, 2007.
28. Takano M, Kato M, Yoshikawa T, Sasaki N, Hirata J, Furuya K, Takahashi M, Yokota H, Kino N, Horie K, Goto T, Fujiwara K, Ishii K, Kikuchi Y and Kita T: Clinical significance of UDPglucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: A prospective multi-institutional study. Oncology 76: 315-321, 2009.
29. Sai K and Saito Y. Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. Expert Opin Drug Metab Toxicol 7: 967-988, 2011.
30. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B and Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 25: 4779-4786, 2011.